Patents by Inventor Karin GUNST

Karin GUNST has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • MSBI SEQUENCES AS AN EARLY MARKER FOR THE FUTURE DEVELOPMENT OF CANCER AND DISEASES OF THE CNS AND AS A TARGET FOR THE TREATMENT AND PREVENTION OF THESE DISEASES
    Publication number: 20220112518
    Abstract: The application relates to MSBI (Multiple Sclerosis Brain Isolate) nucleotide sequences as well as probes and primers comprising part of said nucleotide sequences and antibodies against polypeptides encoded by said nucleotide sequences. These compounds are useful as early markers for the future development of cancer and diseases of the CNS (Multiple sclerosis MS, Prion-linked diseases, amyotrophic lateral sclerosis, transmissible spongiforme encephalitis, Parkinson's disease, Alzheimer disease) and should represent targets for treatment and prevention.
    Type: Application
    Filed: August 20, 2021
    Publication date: April 14, 2022
    Inventors: Ethel-Michele De Villiers-Zur Hausen, Harald Zur Hausen, Karin Gunst, Corinna Whitley, Iranzu Lamberto-Pérez
  • CMI SEQUENCES AS AN EARLY MARKER FOR THE FUTURE DEVELOPMENT OF CANCER, ATHEROSCLEROSIS, DIABETES AND DISEASES OF THE CNS AND AS A TARGET FOR THE TREATMENT AND PREVENTION OF THESE DISEASES
    Publication number: 20220025371
    Abstract: Described are CMI (Cow Milk Isolate) nucleotide sequences as well as probes and primers comprising part of said nucleotide sequences and antibodies against polypeptides encoded by said nucleotide sequences. Said compounds are useful as early markers for the future development of cancer, diabetes, atherosclerosis and diseases of the CNS (Multiple sclerosis MS, Prion-linked diseases, amyotrophic lateral sclerosis, transmissible spongiforme encephalitis, Parkinson's disease, Alzheimer disease) and should represent targets for treatment and prevention.
    Type: Application
    Filed: July 9, 2021
    Publication date: January 27, 2022
    Inventors: Ethel-Michele DE VILLIERS-ZUR HAUSEN, Harald ZUR HAUSEN, Karin GUNST, Timo BUND
  • MSBI SEQUENCES AS AN EARLY MARKER FOR THE FUTURE DEVELOPMENT OF CANCER AND DISEASES OF THE CNS AND AS A TARGET FOR THE TREATMENT AND PREVENTION OF THESE DISEASES
    Publication number: 20200002723
    Abstract: Described are MSBI (Multiple Sclerosis Brain Isolate) nucleotide sequences as well as probes and primers comprising part of said nucleotide sequences and antibodies against polypeptides encoded by said nucleotide sequences. Said compounds are useful as early markers for the future development of cancer and diseases of the CNS (Multiple sclerosis MS, Prion-linked diseases, amyotrophic lateral sclerosis, transmissible spongiforme encephalitis, Parkinson's disease, Alzheimer disease) and should represent targets for treatment and prevention.
    Type: Application
    Filed: March 25, 2019
    Publication date: January 2, 2020
    Inventors: Ethel-Michele De Villiers-Zur Hausen, Harald Zur Hausen, Karin Gunst, Corinna Whitley, Iranzu Lamberto-Pérez
  • HCBI sequences as an early marker for the future development of cancer and diseases of the CNS and as a target for cancer treatment and prevention
    Patent number: 10287335
    Abstract: The present invention relates to HCBI (Healthy Cattle Blood Isolate) nucleotide sequences as well as probes and primers comprising part of said nucleotide sequences and antibodies against polypeptides encoded by said nucleotide sequences. Said compounds are useful as early markers for the future development of cancer and diseases of the CNS.
    Type: Grant
    Filed: April 21, 2016
    Date of Patent: May 14, 2019
    Assignee: DEUTSCHES KREBSFORSCHUNGSZENTRUM
    Inventors: Harald Zur Hausen, Ethel-Michele De Villiers, Karin Gunst, Mathis Funk, Iranzu Lamberto Perez
  • HCBI, MSBI, MSSI AND CMI SEQUENCES AS AN EARLY MARKER FOR THE FUTURE DEVELOPMENT OF CANCER AND DISEASES OF THE CNS AND AS A TARGET FOR THE TREATMENT AND PREVENTION OF THESE DISEASES
    Publication number: 20170198018
    Abstract: Described are HCBI (Healthy Cattle Blood Isolate), MSBI (Multiple Sclerosis Brain Isolate), MSSI (Multiple Sclerosis Serum Isolate) and CMI (Cow Milk Isolate) nucleotide sequences as well as probes and primers comprising part of said nucleotide sequences and antibodies against polypeptides encoded by said nucleotide sequences. Said compounds are useful as early markers for the future development of cancer and diseases of the CNS (Multiple sclerosis MS, Prion-linked diseases, amyotrophic lateral sclerosis, transmissible spongiforme encephalitis, Parkinson's disease, Alzheimer disease) and should represent targets for treatment and prevention.
    Type: Application
    Filed: January 10, 2017
    Publication date: July 13, 2017
    Inventors: Ethel-Michele DE VILLIERS-ZUR HAUSEN, Harald ZUR HAUSEN, Karin GUNST, Corinna WHITLEY, Iranzu Lamberto PEREZ
  • HCBI SEQUENCES AS AN EARLY MARKER FOR THE FUTURE DEVELOPMENT OF CANCER AND DISEASES OF THE CNS AND AS A TARGET FOR CANCER TREATMENT AND PREVENTION
    Publication number: 20160244492
    Abstract: The present invention relates to HCBI (Healthy Cattle Blood Isolate) nucleotide sequences as well as probes and primers comprising part of said nucleotide sequences and antibodies against polypeptides encoded by said nucleotide sequences. Said compounds are useful as early markers for the future development of cancer and diseases of the CNS.
    Type: Application
    Filed: April 21, 2016
    Publication date: August 25, 2016
    Inventors: Harald ZUR HAUSEN, Ethel-Michele DE VILLIERS, Karin GUNST, Mathis FUNK, Iranzu LAMBERTO PEREZ